Biotech Values

[poorgradstudent]

The key takeaway from that piece is the tepid 5-7% growth rate that’s expected by BEC’s buyer. I’m hard-pressed to think of a company selling medical devices or disposables that is growing significantly faster.

I guess.

Just confused about the angle on healthcare reform and rationing and how that applies to BEC.

But then again this is Forbes.


I wonder what impact the stagnant NIH budget has on a company like BEC. That would seem to be a more direct connection with regards to these "tepid" y/y growth rates.